Skip to main content
Fig. 9 | Journal of Experimental & Clinical Cancer Research

Fig. 9

From: Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells

Fig. 9

In vivo tumorous distribution and therapeutic effect of RDMSNs. The content of DOX in tumors treated with RDMSNs was much higher compared with those of other groups at different time points (n = 3). *P < 0.05,** P < 0.01 vs RDMSNs (a). Tumors treated with RDMSNs grew slowly compared to those of other groups. From the 10th day, the mean tumor volume of mice treated with RDMSNs was significantly different compared with those of other groups (b). The mice weight increased gradually with different degrees after injections of saline, DMSNs, and RDMSNs, respectively, while the mice weight in Free DOX groups showed a gentle reduction from the 8th day, indicating that Free DOX had severe systemic toxicity on nude mice. From the 10th day, the mean body weight of mice treated with Free DOX was significantly different compared with those of other groups (c). After 16 days culture, the volumes of tumors treated with saline were significantly larger compared to those of other groups. In contrast, The mice treated with RDMSNs exhibited significant inhibition of tumor growth in volume (d) (n = 5,*P < 0.05,** P < 0.01)

Back to article page